Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.40 |
| ▸ | WNT1 | P04628 | 8/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20054378 | 0.92 | GSK3B (0.37) | GSK3BDYRK1AWNT1HTR1ADRD2 | |
| SCHEMBL20054426 | 0.89 | GSK3B (0.37) | GSK3BDYRK1AWNT1HTR1ADRD2 | |
| SCHEMBL19388305 | 0.77 | GSK3B (0.39) | GSK3BDYRK1AWNT1KCNH2PDPK1 | |
| SCHEMBL15116588 | 0.77 | GSK3B (0.39) | GSK3BDYRK1AWNT1KCNH2PDPK1 | |
| SCHEMBL20054505 | 0.76 | — | — | |
| SCHEMBL20054351 | 0.76 | GSK3B (0.43) | GSK3BDYRK1AWNT1HTR1ADRD2 | |
| SCHEMBL20054506 | 0.73 | GSK3B (0.45) | GSK3BDYRK1AWNT1HTR1ADRD2 | |
| SCHEMBL20054480 | 0.72 | GSK3B (0.61) | GSK3BDYRK1AWNT1 | |
| SCHEMBL15116781 | 0.71 | GSK3B (0.36) | GSK3BDYRK1AWNT1KCNH2 | |
| SCHEMBL19388310 | 0.71 | GSK3B (0.36) | GSK3BDYRK1AWNT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |